Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scientist link blood flow to brain with dementia
The scientists used magnetic resonance imaging (MRI) to examine the brains of elderly patients with and without dementia related to Alzheimer’s or Parkinson’s disease. As expected, MR images
The scientists used magnetic resonance imaging (MRI) to examine the brains of elderly patients with and without dementia related to Alzheimer’s or Parkinson’s disease. As expected, MR images
Discovery and development of new molecule therapies will be based on PPAR (peroxisome proliferator activated receptor) delta agonists which have been shown to play a role in elevating
According to Gilead, the price decreases are due to increased economies of scale, production at a new plant in the Bahamas that manufactures active pharmaceutical ingredient for both
Licensed from one of TAP’s parent companies, Takeda Pharmaceuticals, TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole. “Phase I clinical trial data have
Actoplus met combines the diabetes drugs Actos and metformin. Actos directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and
In the joint venture, the companies plan to identify a series of compounds with the potential of becoming new drugs with further research, and then to partner or
The deal includes BSYX-A110, which is in phase II clinical development for the prevention of serious bloodstream infections caused by staphylococcus in low-birthweight infants. MedImmune will be responsible
Baxter’s Galaxy manufacturing process incorporates the admixture and triple filtration of the therapeutic solution, fills the flexible container in an aseptic environment, and finishes the product as a
After initial pre-clinical development, the company plans to file an investigational new drug application with the FDA and commence clinical trials for SNS-314 in 2006. SNS-314 is a
The process will be based upon Genencor’s technology for large scale manufacture of monoclonal antibodies in fungal systems which can, theoretically, be used to mass produce a number